NLRP3 and cancer: Cancer cells that die, often as a result of therapy, release adenosine triphosphate (ATP), which induces NLR family pyrin domain containing 3 (NLRP3) activation in surviving cancer cells, which then leads to the release of interleukin 1-beta (IL-1β), which in turn can stimulate the formation of NETs (103).